Results 121 to 130 of about 32,676 (224)

Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data

, 2011
Louis M KwongDepartment of Orthopaedic Surgery, Harbor-UCLA Medical Center, Torrance, CA, USAAbstract: Rivaroxaban (Bayer AG, Leverkusen, Germany) is a highly selective direct inhibitor of factor Xa.
Kwong LM
core  

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up

Medicina
Background and Objectives: Rivaroxaban is a direct-acting anticoagulant used to prevent stroke in patients with atrial fibrillation. Rivaroxaban is a substrate for P-glycoprotein, which is encoded by the ABCB1 gene. Rivaroxaban is also metabolized by the
Nur Ul Ain, Niaz Ali, Abid Ullah, Shakir Ullah, Shujaat Ahmad   +4 more
doaj   +1 more source

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, Volume 158, Issue 11, Page 2920-2927, 1 June 2026.
What's new? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Real‐World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Multiple myeloma (MM) carries a high venous thromboembolism (VTE) risk; aspirin shows limited efficacy, while factor‐Xa inhibitors show promise. Objectives Evaluate apixaban for primary thromboprophylaxis in newly diagnosed MM (NDMM).
K. Alexandra Sanchez, Gabriela Cesarman‐Maus, Michelle Flores‐Cruz, Beatriz Cabello, Ramiro Espinoza, Omar Eduardo Fernandez‐Vargas   +5 more
wiley   +1 more source

The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study.

, 2018
BACKGROUND Thromboembolic disease is a potentially serious complication in bariatric surgery patients. Direct oral anticoagulants (DOAC) have been investigated in orthopedic surgery patients.
Bertaggia Calderara, Debora, Stirnimann, G., Kröll, D., Nett, P.C., Nett, Philipp C., Schädelin, S., Schädelin, Sabine, Borbély, Yves Michael, Stirnimann, Guido, Kröll, Dino, Alberio, Lorenzo, Alberio, L., Bertaggia Calderara, D., Borbély, Y.M.   +13 more
core   +1 more source

Direct Oral Anticoagulant Consumption and the Risk of Acute Interstitial Lung Diseases: A Case‐Crossover Study Using Japanese Administrative Data

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background Direct oral anticoagulants (DOACs) offer advantages over warfarin; however, concerns exist regarding their association with acute interstitial lung diseases (ILDs). This study investigated the risk of acute‐onset ILDs associated with DOAC use.
Keisuke Anan, Takahiro Itaya, Yuki Kataoka, Kazuya Ichikado, Kodai Kawamura, Yosuke Yamamoto   +5 more
wiley   +1 more source

Thrombosis and bleeding outcomes with warfarin conversion to rivaroxaban during the COVID-19 pandemic

South African Medical Journal
Background. In 2020, during the coronavirus disease 2019 (COVID‐19) outbreak, eligible patients were converted from warfarin to rivaroxaban therapy to limit the transmission of COVID‐19 infection. Objective.
C-Y Wang, E Schapkaitz, S Louw, B Jacobson   +3 more
doaj   +1 more source

Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 6, June 2026.
ABSTRACT Background Drug interactions involving immunosuppressants can compromise transplant outcomes. Although repeated ketamine administration induces hepatic enzymes in experimental models, clinical reports of induced clearance of cytochrome P450 (CYP) substrates are lacking. Continuous subcutaneous ketamine infusions are increasingly used for acute
Jana Stojanova, Bridin Murnion, Fay Burrows, Lilibeth Carlos, Tomoyuki Mizuno, Takanobu Nadai, Kei Irie, Nuala Helsby, Kavitha Muthiah, Richard Day   +9 more
wiley   +1 more source

Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities ...
Shea Hogan, Michael Szarek, E. Sebastian Debus, Mark Nehler, Sonia S. Anand, Manesh R. Patel, Akos Ferenc Pap, Hsiaowei Deng, Sophie Hodge, Lloyd P. Haskell, Eva Muehlhofer, Scott E. Berkowitz, Rupert M. Bauersachs, Marc P. Bonaca   +13 more
doaj   +1 more source

Comparative Bleeding Risk of Brand Vs Generic Rivaroxaban in Elderly Inpatients with Atrial Fibrillation

Guoquan Chen,1,* Jiale Chen,1,* Qiang Zhao,2 Yalan Zhu1 1Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, 321000, People’s Republic of China; 2Department of Cardiology, Affiliated Jinhua Hospital,
Chen J, Zhu Y, Zhao Q, Chen G
core